Predictors of mortality in patients with yellow fever: an observational cohort study

Imagem de Miniatura
Arquivos
art_KALLAS_Predictors_of_mortality_in_patients_with_yellow_fever_2019.PDF (629.3 KB)
Citações na Scopus
45
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
BUCCHERI, Renata
DINIZ, Gabriela B. F.
CASTINEIRAS, Anna Carla P.
Citação
LANCET INFECTIOUS DISEASES, v.19, n.7, p.750-758, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Yellow fever virus infection results in death in around 30% of symptomatic individuals. The aim of this study was to identify predictors of death measured at hospital admission in a cohort of patients admitted to hospital during the 2018 outbreak of yellow fever in the outskirts of Sao Paulo city, Brazil. Methods In this observational cohort study, we enrolled patients with yellow fever virus from two hospitals in Sao Paolo-the Hospital das Clinicas, University of Sao Paulo and the Infectious Diseases Institute ""Emilio Ribas"". Patients older than 18 years admitted to hospital with fever or myalgia, headache, arthralgia, oedema, rash, or conjunctivitis were consecutively screened for inclusion in the present study. Consenting patients were included if they had travelled to geographical areas in which yellow fever virus cases had been previously confirmed. Yellow fever infection was confirmed by real-time PCR in blood collected at admission or tissues at autopsy. We sequenced the complete genomes of yellow fever virus from infected individuals and evaluated demographic, clinical, and laboratory findings at admission and investigated whether any of these measurements correlated with patient outcome (death). Findings Between Jan 11, 2018, and May 10, 2018, 118 patients with suspected yellow fever were admitted to Hospital das Clinicas, and 113 patients with suspected yellow fever were admitted to Infectious Diseases Institute ""Emilio Ribas"". 95 patients with suspected yellow fever were included in the study, and 136 patients were excluded. Three (3%) of 95 patients with suspected yellow fever who were included in the study were excluded because they received a different diagnosis, and 16 patients with undetectable yellow fever virus RNA were excluded. Therefore, 76 patients with confirmed yellow fever virus infection, based on detectable yellow fever virus RNA in blood (74 patients) or yellow fever virus confirmed only at the autopsy report (two patients), were included in our analysis. 27 (36%) of 76 patients died during the 60 day period after hospital admission. We generated 14 complete yellow fever virus genomes from the first 15 viral load-detectable samples. The genomes belonged to a single monophyletic clade of the South America I genotype, sub-genotype E. Older age, male sex, higher leukocyte and neutrophil counts, higher alanine aminotransferase, aspartate transaminase (AST), bilirubin, and creatinine, prolonged prothrombin time, and higher yellow fever virus RNA plasma viral load were associated with higher mortality. In a multivariate regression model, older age, elevated neutrophil count, increased AST, and higher viral load remained independently associated with death. All 11 (100%) patients with neutrophil counts of 4000 cells per mL or greater and viral loads of 5.1 log(10) copies/mL or greater died (95% CI 72-100), compared with only three (11%) of 27 (95% CI 2-29) among patients with neutrophil counts of less than 4000 cells per mL and viral loads of less than 5.1 log(10) copies/mL. Interpretation We identified clinical and laboratory predictors of mortality at hospital admission that could aid in the care of patients with yellow fever virus. Identification of these prognostic markers in patients could help clinicians prioritise admission to the intensive care unit, as patients often deteriorate rapidly. Moreover, resource allocation could be improved to prioritise key laboratory examinations that might be more useful in determining whether a patient could have a better outcome. Our findings support the important role of the virus in disease pathogenesis, suggesting that an effective antiviral could alter the clinical course for patients with the most severe forms of yellow fever.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/33102
Referências
  1. Aguiar BS, 2018, INT J INFECT DIS, V70, P20, DOI 10.1016/j.ijid.2018.02.007
  2. [Anonymous], 2017, Wkly Epidemiol Rec, V92, P442
  3. Bae HG, 2003, J VIROL METHODS, V110, P185, DOI 10.1016/S0166-0934(03)00129-0
  4. Beeuwkes H., 1936, T R SOC TROP MED HYG, V30, P61, DOI 10.1016/S0035-9203(36)90014-7
  5. Blake LE, 2014, MBIO, V5, DOI 10.1128/mBio.01253-14
  6. de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
  7. Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
  8. Engelmann F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003295
  9. Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
  10. Fernandes-Monteiro AG, 2015, HUM VACC IMMUNOTHER, V11, P1865, DOI 10.4161/21645515.2014.990854
  11. Fischer C, 2017, EMERG INFECT DIS, V23, P1867, DOI 10.3201/eid2311.171131
  12. Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
  13. Grobbelaar AA, 2016, EMERG INFECT DIS, V22, P1854, DOI 10.3201/eid2210.160818
  14. Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
  15. Hughes HR, 2018, EMERG INFECT DIS, V24, P1598, DOI 10.3201/eid2408.180588
  16. Julander JG, 2014, ANTIVIR RES, V103, P32, DOI 10.1016/j.antiviral.2013.12.011
  17. Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI 10.1016/S1473-3099(16)30513-8
  18. Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
  19. Massad E, 2018, EPIDEMIOL INFECT, V146, P1219, DOI [10.1017/S0950268818001334, 10.1017/s0950268818001334]
  20. Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
  21. Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
  22. Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
  23. Nunes PCG, 2018, VIRUSES, V10, pE236
  24. Plotkin SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay130
  25. Quaresma JAS, 2013, REV MED VIROL, V23, P305, DOI 10.1002/rmv.1752
  26. Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
  27. Rowe EK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002777
  28. Secretary of Health State of Sao Paulo, 2018, B EP FEBR AM
  29. Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
  30. Song ATW, 2019, HEPATOLOGY, V69, P1349, DOI 10.1002/hep.30273
  31. ter Meulen J, 2004, J INFECT DIS, V190, P1821, DOI 10.1086/425016
  32. Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
  33. van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
  34. Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
  35. Wilder-Smith A, 2017, J TRAVEL MED, V24, P1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - LIM/46
Carregar mais